XML 62 R41.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Legal Proceedings, Commitments and Contingencies - Additional Information (Detail) $ in Thousands |  |  |  |  |  |  | 1 Months Ended | 6 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 08, 2017 USD ($) | Jul. 24, 2017 USD ($) | Apr. 10, 2017 USD ($) | Dec. 22, 2016 USD ($) | Jun. 24, 2016 USD ($) | Jun. 06, 2016 USD ($) shares | Jul. 31, 2016 USD ($) shares | Dec. 31, 2015 USD ($) | Jun. 30, 2017 USD ($) shares | Dec. 31, 2016 USD ($) Defendant shares | Dec. 31, 2015 USD ($) | Dec. 31, 2014 USD ($) | Feb. 23, 2017 Counts Witness
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Total number of shares cancelled | shares |  |  |  |  |  |  |  |  | 161,000 | 240,000 |  |  |
Damages paid by insurance companies |  |  |  |  |  |  |  |  |  | $ 21,700 |  |  |
Payable by the company in cash |  |  |  |  |  |  |  |  |  | 2,450 |  |  |
Litigation settlement payable in common stock |  |  |  |  |  |  |  |  |  | 2,650 | $ 1,000 | $ 0 |
Litigation settlement, amount |  |  |  |  |  |  |  |  |  | 27,750 |  |  |
Asset Purchase Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, estimate of possible loss |  |  |  |  |  |  |  |  | $ 1,500 |  |  |  |
Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement, amount |  |  |  |  |  |  |  |  |  | 5,000 |  |  |
Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement, amount |  |  |  |  |  |  |  |  |  | 20,000 |  |  |
SEC Litigation |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement, amount |  |  |  |  |  |  |  |  |  | 950 |  |  |
SEC Litigation | Indemnification Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Guarantor obligations |  |  | $ 750 | $ 750 |  |  |  |  |  | $ 750 |  |  |
SEC Litigation | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payable by the company in cash | $ 100 |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement with issuance of common stock | $ 200 |  |  |  |  |  |  |  |  |  |  |  |
Settled Litigation | Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Legal fees |  |  |  |  | $ 4,500 |  |  |  |  |  |  |  |
Settled Litigation | Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Legal fees |  |  |  |  | 4,500 |  |  |  |  |  |  |  |
Settlement payment |  |  |  |  | $ 20,000 | $ 20,000 |  |  |  |  |  |  |
Damages paid by insurance companies |  |  |  |  |  | 16,700 |  |  |  |  |  |  |
Damages paid |  |  |  |  |  | 3,300 |  |  |  |  |  |  |
Payable by the company in cash |  |  |  |  |  | 2,300 |  |  |  |  |  |  |
Litigation settlement payable in common stock |  |  |  |  |  | $ 1,000 |  |  |  |  |  |  |
Litigation settlement, issuance of shares, shares | shares |  |  |  |  |  | 24,002 |  |  |  |  |  |  |
Attorney fees |  |  |  |  |  |  |  | $ 2,000 |  |  |  |  |
Settled Litigation | Securities Litigation, Opt Out Settlement, Case 1 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement, issuance of shares, shares | shares |  |  |  |  |  |  | 14,563 |  |  |  |  |  |
Litigation settlement, amount |  |  |  |  |  |  | $ (150) |  |  |  |  |  |
Litigation settlement with issuance of common stock |  |  |  |  |  |  | $ 150 |  |  |  |  |  |
Settled Litigation | Securities Litigation, Opt Out Settlement, Case 2 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement, issuance of shares, shares | shares |  |  |  |  |  |  | 168,337 |  |  |  |  |  |
Litigation settlement with issuance of common stock |  |  |  |  |  |  | $ 1,500 |  |  |  |  |  |
Settled Litigation | USAO NJ and DOJ |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement, amount |  |  |  |  |  |  |  |  | 7,500 |  |  |  |
Settled Litigation | Director [Member] | Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Total number of shares cancelled | shares |  |  |  |  |  |  |  |  |  | 60,000 |  |  |
Settled Litigation | Maximum | Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Settlement payment |  |  |  |  |  |  |  |  |  | $ 15,000 |  |  |
Judicial Ruling [Member] | SDAL Criminal Case for Alleged Violations of the False Claims Act and Other Federal Statutes [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of defendants | Defendant |  |  |  |  |  |  |  |  |  | 2 |  |  |
Judicial Ruling [Member] | SDAL Criminal Case for Alleged Violations of the False Claims Act and Other Federal Statutes [Member] | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of counts against defendants with judicial ruling of guilty | Counts |  |  |  |  |  |  |  |  |  |  |  |  | 19
Number of counts against defendants | Counts |  |  |  |  |  |  |  |  |  |  |  |  | 20
Judicial Ruling [Member] | Former Employee [Member] | SDAL Criminal Case for Alleged Violations of the False Claims Act and Other Federal Statutes [Member] | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of witness to testify at trial | Witness |  |  |  |  |  |  |  |  |  |  |  |  | 1
Pending Litigation | SEC Litigation |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement, amount |  |  | (200) | (200) |  |  |  |  |  |  |  |  |
Pending Litigation | Patel vs Galena biopharma, Inc | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payable by the company in cash |  | $ 50 |  |  |  |  |  |  |  |  |  |  |
Litigation settlement, amount |  | 1,300 |  |  |  |  |  |  |  |  |  |  |
Litigation settlement with issuance of common stock |  | $ 1,250 |  |  |  |  |  |  |  |  |  |  |
Pending Litigation | Former CEO [Member] | SEC Litigation |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Litigation settlement, amount |  |  | $ (600) | $ (600) |  |  |  |  |  |  |  |  |
Commercial Business Segment | Settled Litigation | USAO NJ and DOJ |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual |  |  |  |  |  |  |  |  | $ 7,500 |  |  |  |

X
- Definition Issuance of Common Stock for Litigation Settlement + References No definition available. + Details
Name: | gale_IssuanceofCommonStockforLitigationSettlement
Namespace Prefix: | gale_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Litigation Settlement, Issuance of Common Stock, Shares + References No definition available. + Details
Name: | gale_LitigationSettlementIssuanceofCommonStockShares
Namespace Prefix: | gale_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Litigation settlement, issuance of common stock, value. + References No definition available. + Details
Name: | gale_LitigationSettlementIssuanceofCommonStockValue
Namespace Prefix: | gale_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Loss Contingency, Damages Paid by Insurance Company, Value + References No definition available. + Details
Name: | gale_LossContingencyDamagesPaidbyInsuranceCompanyValue
Namespace Prefix: | gale_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Loss Contingency, Number of Witness to Testify at Trial + References No definition available. + Details
Name: | gale_LossContingencyNumberofWitnesstoTestifyatTrial
Namespace Prefix: | gale_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Counts Against Defendants + References No definition available. + Details
Name: | gale_NumberofCountsAgainstDefendants
Namespace Prefix: | gale_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Counts Against Defendants with Judicial Ruling of Guilty + References No definition available. + Details
Name: | gale_NumberofCountsAgainstDefendantswithJudicialRulingofGuilty
Namespace Prefix: | gale_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12069-110248 + Details
Name: | us-gaap_GuaranteeObligationsCurrentCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LegalFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of judgment or settlement awarded to (against) the entity in respect of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of loss contingency liability. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of damages awarded to the plaintiff in the legal matter. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349 + Details
Name: | us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of damages paid to the plaintiff in the legal matter. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349 + Details
Name: | us-gaap_LossContingencyDamagesPaidValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reflects the estimated amount of loss from the specified contingency as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349 + Details
Name: | us-gaap_LossContingencyEstimateOfPossibleLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of defendants named in a legal action. + References No definition available. + Details
Name: | us-gaap_LossContingencyNumberOfDefendants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash paid for the settlement of litigation or for other legal issues during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForLegalSettlements
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07.2(a),(b),(c),(d)) -URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section 45 -Paragraph 3 -Subparagraph (k) -URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849 + Details
Name: | us-gaap_ProfessionalFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(3) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=gale_AssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.DerivativeLitigationCivilActionNo.314cv00382SIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=gale_GalenaBiopharmaInc.SecuritiesLitigationCivilActionNo.314cv00367SIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=gale_SECLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_IndemnificationGuaranteeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=gale_SecuritiesLitigationOptOutSettlementCase1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=gale_SecuritiesLitigationOptOutSettlementCase2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=gale_U.S.AttorneysOfficeForTheDistrictOfNewJerseyAndDepartmentOfJusticeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=gale_SDALCriminalCaseforAllegedViolationsoftheFalseClaimsActandOtherFederalStatutesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=gale_FormerEmployeeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationCaseAxis=gale_PatelvsGalenabiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=gale_FormerCEOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=gale_CommercialBusinessSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |